What is Schrodinger?
Founded in 1990, Schrodinger provides an advanced software platform that integrates physics-based modeling with machine learning to accelerate innovation in drug discovery and materials science. By enabling researchers to simulate molecular interactions with high precision, the company has become an essential partner for organizations in the pharmaceutical, biotechnology, and electronics industries. Schrodinger's global footprint, spanning the United States, Europe, Japan, and India, allows it to maintain a robust ecosystem of business partnerships that drive scientific breakthroughs. The company's unique value proposition lies in its ability to reduce the time and cost associated with traditional laboratory experimentation, effectively digitizing the R&D process for enterprise-level clients.
How much funding has Schrodinger raised?
Schrodinger has raised a total of $151M across 5 funding rounds:
Other Financing Round
$10M
Other Financing Round
$20M
Other Financing Round
$22M
Unspecified
$85M
Series A
$14M
Other Financing Round (2010): $10M with participation from Cascade Investment
Other Financing Round (2012): $20M led by Bill Gates
Other Financing Round (2015): $22M supported by Scott Becker
Unspecified (2019): $85M featuring Baron, WuXi AppTec's Corporate Venture Fund, Deerfield, Bill & Melinda Gates Foundation, Qiming Venture Partners, and GV
Series A (2020): $14M backed by Grey Wolf Therapeutics, Andera Partners, and Canaan
Key Investors in Schrodinger
Canaan
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
Cascade Investment
Cascade Investment Group is a financial services firm with over 100 years of combined investment experience, dedicated to enhancing clients' financial well-being through personalized wealth management and asset allocation.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models.
What's next for Schrodinger?
With the recent influx of capital, Schrodinger is well-positioned to scale its enterprise software offerings and deepen its integration of artificial intelligence within its simulation workflows. The strategic focus will likely center on expanding its reach into emerging markets and enhancing its computational infrastructure to support increasingly complex materials design projects. As the company continues to leverage its physics-based modeling expertise, it remains a key player in the digital transformation of the life sciences sector. Investors and industry analysts will be monitoring how the firm utilizes this latest financing to maintain its competitive edge and accelerate the development of next-generation therapeutic and material solutions.
See full Schrodinger company page
